Asthma Precision

  • Fang Chen
  • Jia-Ying Zhang
  • Hong-Kuan Yang
  • Fang Wang
Part of the Translational Bioinformatics book series (TRBIO, volume 12)


Asthma is a complex and heterogeneous disease, as the reaction to recommended treatmens varies with each individual, especially for refractory and severe asthma. Cluster analysis has helped us to distinguish the different features of asthma phenotype according to asthma patient population, clinical symptoms and pathophysiological changes, and due to advances of omics sequencing in genomics and proteomics, we can detect asthma biomarkers derived from multiple specimens, accurately and quickly finding the pathogenesis of asthma. These progresses have promoted the personalized therapy of asthma. Many targeted drugs aiming to small molecules that had changed in the process of asthma have already obtained the initial efficacy in clinical trials. In addition, the safety and effectiveness of bronchial thermoplasty have also been affirmed. This article mainly focuses on these selected therapeutic targets therapies.


Asthma Personalized therapy Precision medicine Bronchial thermoplasty 



The American Academy of Allergy, Asthma and Immunology


asthma control questionnaire


antibody-dependent cell-mediated cytotoxicity


absolute eosinophil count


airway hyperreactivity


asthma quality of life questionnaire


airway smooth muscle




bronchial hyperresponsiveness


body mass index


chronic obstructive pulmonary disease


continuous positive airway pressure


C-reactive protein


chemoattractant receptor–homologous


C-X-C chemokine receptor type2


emergency department


Food and Drug Administration


fractional exhaled nitric oxide


forced expired volume in 1 s


Global Initiative for Asthma


hazard ratio


inhaled corticosteroids/ corticosteroids


interleukin 13


interleukin 17


interleukin 4


interleukin 5


group 2 innate lymphoid cells


long-acting β-agonists




oral corticosteroids


peak expiratory flow


prostaglandin D2


precision medicine


quality-adjusted life year


randomized controlled trial


tumor necrosis factor-α


  1. 1.
    Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126:926–38. [PubMed:20926125]PubMedCrossRefGoogle Scholar
  2. 2.
    Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–24. [PubMed:18480428]PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315–23. [PubMed:19892860]PubMedCrossRefGoogle Scholar
  4. 4.
    Dixon AE, Poynter ME. Mechanisms of asthma in obesity: pleiotropic aspects of obesity produce distinct asthma phenotypes. Am J Respir Cell Mol Biol. 2016;54:601–8. [PubMed:26886277]PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Wood LG, Garg ML, Gibson PG. A high-fat challenge increases airway inflammation and impairs bronchodilator recovery in asthma. J Allergy Clin Immunol. 2011;127:1133–40. [PubMed:21377715]PubMedCrossRefGoogle Scholar
  6. 6.
    Karakaya G, Celebioglu E, Kalyoncu AF. Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma. Respir Med. 2013;107:967–74. [PubMed:23643317]PubMedCrossRefGoogle Scholar
  7. 7.
    Sofianou A, Martynenko M, Wolf MS, et al. Asthma beliefs are associated with medication adherence in older asthmatics. J Gen Intern Med. 2013;28:67–73. [PubMed:22878848]PubMedCrossRefGoogle Scholar
  8. 8.
    Krieger JW, Takaro TK, Song L, et al. The Seattle-King County Healthy Homes Project: a randomized, controlled trial of a community health worker intervention to decrease exposure to indoor asthma triggers. Am J Public Health. 2005;95:652–9. [PubMed:15798126]PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Diaz J, Farzan S. Clinical implications of the obese–asthma phenotypes. Immunol Allergy Clin N Am. 2014;34:739–51. [PubMed:25282287]CrossRefGoogle Scholar
  10. 10.
    Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – an EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72:1297–305. [PubMed:28306159]PubMedCrossRefGoogle Scholar
  11. 11.
    Gibson PG, Peters MJ, Wainwright CE. Targeted therapy for chronic respiratory disease: a new paradigm. Med J Aust. 2017;206:136–40. [PubMed:28208047]PubMedCrossRefGoogle Scholar
  12. 12.
    Ferrando M, Bagnasco D, Varricchi G, et al. Personalized medicine in allergy. Allergy, Asthma Immunol Res. 2017;9:15–24. [PubMed:27826958]CrossRefGoogle Scholar
  13. 13.
    Guilleminault L, Ouksel H, Belleguic C, et al. Personalised medicine in asthma: from curative to preventive medicine. Eur Respir Rev. 2017;26(143):160010. [PubMed:28049214]PubMedCrossRefGoogle Scholar
  14. 14.
    Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583–93. [PubMed:15172898]PubMedCrossRefGoogle Scholar
  15. 15.
    Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459–65. [PubMed:15753888]PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004;113:297–302. [PubMed:14767445]PubMedCrossRefGoogle Scholar
  17. 17.
    Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73. [PubMed:24337046]PubMedCrossRefGoogle Scholar
  18. 18.
    Humbert M, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–16. [PubMed:15679715]PubMedCrossRefGoogle Scholar
  19. 19.
    Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559. [PubMed:24414989]Google Scholar
  20. 20.
    Chen H, Eisner MD, Haselkorn T, Trzaskoma B. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Respir Med. 2013;107:60–7. [PubMed:23083840]PubMedCrossRefGoogle Scholar
  21. 21.
    Braunstahl GJ, Chlumsky J, Peachey G, Chen CW. Reduction inoral corticosteroid use in patients receiving omalizumab for allergicasthma in the real-world setting. Allergy Asthma Clin Immunol. 2013;9:47. [PubMed: 24305549]PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–82. [PubMed: 21536936]PubMedCrossRefGoogle Scholar
  23. 23.
    Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–11. [PubMed: 23471469]PubMedCrossRefGoogle Scholar
  24. 24.
    Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134:560–7. [PubMed: 24679845]PubMedCrossRefGoogle Scholar
  25. 25.
    Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191. [PubMed:25645133]PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Nopp A, Johansson SG, Adédoyin J, et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65:56–60. [PubMed:19796193]PubMedCrossRefGoogle Scholar
  27. 27.
    Gauvreau GM, Arm JP, Boulet LP, Leigh R, Cockcroft DW, DAvis BE, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol. 2016;138:1051–9. [PubMed:27185571]PubMedCrossRefGoogle Scholar
  28. 28.
    Kanda A, Driss V, Hornez N, Abdallah M, Roumier T, Abboud G, et al. Eosinophil-derived IFN-gamma induces airway hyperresponsiveness and lung inflammation in the absence of lymphocytes. J Allergy Clin Immunol. 2009; 124(3):573–82, 82.e1-9. [PubMed:19539982]Google Scholar
  29. 29.
    Wang FP, Liu T, Lan Z, et al. Efficacy and safety of anti-interleukin-5Therapy in patients with asthma: a systematic review and meta-analysis. PLoS One. 2016;11:e0166833. [PubMed:27875559]PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Nair P, Pizzichini M, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93. [PubMed:19264687]PubMedCrossRefGoogle Scholar
  31. 31.
    Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–84. [PubMed:19264686]PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Prazma CM, Wenzel S, Barnes N, Douglass JA, Hartley BF, Ortega H. Characterisation of an OCS-dependent severe asthma population treated with mepolizumab. Thorax. 2014;69:1141–2. [PubMed:28434924]PubMedCrossRefGoogle Scholar
  33. 33.
    Pavord I, Kom S, Bleecker E, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–9. [PubMed:22901886]PubMedCrossRefGoogle Scholar
  34. 34.
    Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–97. [PubMed:25199060]PubMedCrossRefGoogle Scholar
  35. 35.
    Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–207. [PubMed:25199059]PubMedCrossRefGoogle Scholar
  36. 36.
    Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multicenter, open-label, phase IIIb study. Clin Ther. 2016;38:2058–70. [PubMed:27553751]PubMedCrossRefGoogle Scholar
  37. 37.
    Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanizedanti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344–1353.e2. [PubMed:20513525]PubMedCrossRefGoogle Scholar
  38. 38.
    Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–9. [PubMed:26775606]PubMedCrossRefGoogle Scholar
  39. 39.
    Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086–96. e5. [PubMed:23866823]PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2:879–90. [PubMed:25306557]PubMedCrossRefGoogle Scholar
  41. 41.
    Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosageinhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–27. [PubMed:27609408]PubMedCrossRefGoogle Scholar
  42. 42.
    FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an antiinterleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–41. [PubMed:27609406]PubMedCrossRefGoogle Scholar
  43. 43.
    Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Respir Med. 2017;5:568–76. [PubMed:28545978]Google Scholar
  44. 44.
    Castro M, Mathur S, Hargreave P, et al. Reslizumab for poorly controlled eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125–32. [PubMed:21852542]PubMedCrossRefGoogle Scholar
  45. 45.
    Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated bloodeosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3trials. Lancet Respir Med. 2015;3:e15. [PubMed:25890659]PubMedCrossRefGoogle Scholar
  46. 46.
    Maselli DJ, Velez MI, Rogers L. Reslizumab in the management of poorly controlled asthma: the data so far. J Asthma Allergy. 2016;9:155–62. [PubMed:27621657]PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Perkins C, Wills-Karp M, Finkelman FD. IL-4 induces IL-13-independent allergic airway inflammation. J Allergy Clin Immunol. 2006;118:410–9. [PubMed:16890766]PubMedCrossRefGoogle Scholar
  48. 48.
    Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. 2008;121(3):685–91. [PubMed:18328894]PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–66. [PubMed:23688323]PubMedCrossRefGoogle Scholar
  50. 50.
    Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9. [PubMed:25006719]PubMedCrossRefGoogle Scholar
  51. 51.
    Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181:788–96. [PubMed:20056900]PubMedCrossRefGoogle Scholar
  52. 52.
    Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–98. [PubMed:21812663]PubMedCrossRefGoogle Scholar
  53. 53.
    Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II):replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781–96. [PubMed:27616196]PubMedCrossRefGoogle Scholar
  54. 54.
    Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748–56. [PubMed:26001563]PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330–8. [PubMed:22743678]PubMedCrossRefGoogle Scholar
  56. 56.
    Brightling CE, Chanez P, Leigh R, O’Byrne PM, Korn S, She D, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:692–701. [PubMed:26231288]PubMedCrossRefGoogle Scholar
  57. 57.
    De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133:989–96. [PubMed:24582316]PubMedCrossRefGoogle Scholar
  58. 58.
    Dias-Júnior SA, Reis M, de Carvalho-Pinto RM, et al. Effects of weight loss on asthma control in obese patients with severe asthma. Eur Respir J. 2014;43:1368–77. [PubMed:24232701]PubMedCrossRefGoogle Scholar
  59. 59.
    Jensen ME, Gibson PG, Collins CE, et al. Diet-induced weight loss in obese children with asthma: a randomized controlled trial. Clin Exp Allergy. 2013;43:775–84. [PubMed:23786284]PubMedCrossRefGoogle Scholar
  60. 60.
    Luna-Pech JA, Torres-Mendoza BM, Luna-Pech JA, et al. Normocaloric diet improves asthma-related quality of life in obese pubertal adolescents. Int Arch Allergy Immunol. 2014;163:252–8. [PubMed:24713632]PubMedCrossRefGoogle Scholar
  61. 61.
    Scott HA, Gibson PG, Garg ML, et al. Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial. Clin Exp Allergy. 2013;43:36–49. [PubMed:23278879]PubMedCrossRefGoogle Scholar
  62. 62.
    Reddy RC, Baptist AP, Fan Z, et al. The effects of bariatric surgery on asthma severity. Obes Surg. 2011;21:200–6. [PubMed:20393807]PubMedCrossRefGoogle Scholar
  63. 63.
    Boulet LP, Turcotte H, Martin J, et al. Effect of bariatric surgery on airway response and lung function in obese subjects with asthma. Respir Med. 2012;106:651–60. [PubMed:22326605]PubMedCrossRefGoogle Scholar
  64. 64.
    Desai LP, Wu Y, Tepper RS, et al. Mechanical stimuli and IL-13 interact at integrin adhesion complexes to regulate expression of smooth muscle myosin heavy chain in airway smooth muscle tissue. Am J Physiol Lung Cell Mol Physiol. 2011;301:L275–84. [PubMed:21642449]PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Busk M, Busk N, Puntenney P, et al. Use of continuous positive airway pressure reduces airway reactivity in adults with asthma. Eur Respir J. 2012;41:317–22. [PubMed:22835615]PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo controlled trial. Lancet. 2012;380:660–7. [PubMed:22901887]PubMedCrossRefGoogle Scholar
  67. 67.
    Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–9. [PubMed:23532241]PubMedCrossRefGoogle Scholar
  68. 68.
    Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–98. [PubMed:21864166]PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma(AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68:322–9. [PubMed:23291349]PubMedCrossRefGoogle Scholar
  70. 70.
    Good Jr JT, Rollins DR, Martin RJ. Macrolides in the treatment of asthma. Curr Opin Pulm Med. 2012;18:76–84. [PubMed:22112996]CrossRefGoogle Scholar
  71. 71.
    Hahn DL, Grasmick M, Hetzel S, Yale S. Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med. 2012;25:442–59. [PubMed:22773713]PubMedCrossRefGoogle Scholar
  72. 72.
    Licona-Limón P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. 2013;14:536–42. [PubMed:23685824]PubMedCrossRefGoogle Scholar
  73. 73.
    Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42:1097–103. [PubMed:22702508]PubMedCrossRefGoogle Scholar
  74. 74.
    Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294–302. [PubMed:24200404]PubMedCrossRefGoogle Scholar
  75. 75.
    Tillie-Leblond I, Germaud P, Leroyer C. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy. 2011;66:1254–6. [PubMed:21517902]PubMedCrossRefGoogle Scholar
  76. 76.
    Chishimba L, Niven RM, Cooley J, et al. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma. 2012;49:423–33. [PubMed:22380765]PubMedCrossRefGoogle Scholar
  77. 77.
    Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T, et al. Arandomized, double-blind, placebo-controlled study of the CRTH2antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2012;42:38–48. [PubMed:21762224]PubMedCrossRefGoogle Scholar
  78. 78.
    Pettipher R, Hunter MG, Perkins CM, Collins LP, Lewis T, Baillet M, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;69:1223–32. [PubMed:24866478]PubMedCrossRefGoogle Scholar
  79. 79.
    Hall IP, Fowler AV, Gupta A, Tetzlaff K, Nivens MC, Sarno M, et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther. 2015;32:37–44. [PubMed:25861737]PubMedCrossRefGoogle Scholar
  80. 80.
    Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549–58. [PubMed:19136369]PubMedCrossRefGoogle Scholar
  81. 81.
    Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354:697–708. [PubMed:16481637]PubMedCrossRefGoogle Scholar
  82. 82.
    Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax. 2008;63:584–91. [PubMed:18245148]PubMedCrossRefGoogle Scholar
  83. 83.
    Mullarkey MF, Lammert JK, Blumenstein BA. Long-term methotrexate treatment incorticosteroid-dependent asthma. Ann Intern Med. 1990;112:577–81. [PubMed:2327677]PubMedCrossRefGoogle Scholar
  84. 84.
    Erzurum SC, Leff JA, Cochran JE, Ackerson LM, Szefler SJ, Martin RJ, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study. Ann Intern Med. 1991;114:353–60. [PubMed:1992876]PubMedCrossRefGoogle Scholar
  85. 85.
    Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev. 2000:CD000391. [PubMed:10796540]Google Scholar
  86. 86.
    Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE, TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy. 2007;62:126–33. [PubMed:17298420]PubMedGoogle Scholar
  87. 87.
    Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res. 2017;9:3–14. [PubMed:27826957]PubMedCrossRefGoogle Scholar
  88. 88.
    Cox PG, Miller J, Mitzner W, et al. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J. 2004;24:659–63. [PubMed:15459147]PubMedCrossRefGoogle Scholar
  89. 89.
    Benayoun L, Druilhe AM, Aubier M, et al. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med. 2003;167:1360–8. [PubMed:12531777]PubMedCrossRefGoogle Scholar
  90. 90.
    Danek CJ, Lombard CM, Dungworth DL, Cox PG, Miller JD, Biggs MJ, Keast TM, Loomas BE, Wizeman WJ, Hogg JC, et al. Reduction in airway hyper responsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol. 2004;97:1946–53. [PubMed:15258133]PubMedCrossRefGoogle Scholar
  91. 91.
    Brown RH, Wizeman W, Danek C, et al. In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography. J Appl Physiol. 2005;98:1603–6. [PubMed:15718404]PubMedCrossRefGoogle Scholar
  92. 92.
    Dyrda P, Tazzeo T, Doharris L, et al. Acute response of airway muscle to extreme temperature includes disruption of actin-myosin interaction. Am J Respir Cell Mol Biol. 2011;44:213–21. [PubMed:20395634]PubMedCrossRefGoogle Scholar
  93. 93.
    Miller JD, Cox G, Vincic L, et al. A prospective feasibility study of bronchial thermoplasty in the human airway. Chest. 2005;127(6):1999–2006. [PubMed:15947312]PubMedCrossRefGoogle Scholar
  94. 94.
    Cox G, Thomson NC, Rubin AS, Niven RM, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007;356:1327–37. [PubMed:17392302]PubMedCrossRefGoogle Scholar
  95. 95.
    Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;176:1185–91. [PubMed:17901415]PubMedCrossRefGoogle Scholar
  96. 96.
    Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181:116–24. [PubMed:19815809]PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Burn J, Sims AJ, Keltie K, et al. Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and hospital episode statistics. J Asthma. 2017;54:872–9. [PubMed:27905828]PubMedCrossRefGoogle Scholar
  98. 98.
    Doeing DC, Mahajan AK, White SR, et al. Safety and feasibility of bronchial thermoplasty in asthma patients with very severe fixed airflow obstruction: a case series. J Asthma. 2013;50:215–8. [PubMed:23252954]PubMedCrossRefGoogle Scholar
  99. 99.
    Chanez P, Boulet LP, Brillet PY, et al. Bronchial thermoplasty in the treatment of severe adult asthma. Rev Mal Respir. 2015;32:97–109. [PubMed:25534552]PubMedCrossRefGoogle Scholar
  100. 100.
    Cox G, Miller JD, McWilliams A, et al. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med. 2006;173:965–9. [PubMed:16456145]PubMedCrossRefGoogle Scholar
  101. 101.
    Pavord ID, Thomson NC, Niven RM, Corris PA, Chung KF, Cox G, Armstrong B, Shargill NS, Laviolette M. Research in severe asthma trial study group. Safety of bronchial thermoplasty in patients with severe refractory asthma. Ann Allergy Asthma Immunol. 2013;111:402–7. [PubMed:24125149]PubMedCrossRefGoogle Scholar
  102. 102.
    Wechsler ME, Laviolette M, Rubin AS, et al. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013;132:1295–302. [PubMed:23998657]PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Cangelosi MJ, Ortendahl JD, Meckley LM, et al. Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. Expert Rev Pharmacoecon Outcomes Res. 2015;15:357–64. [PubMed:25363000]PubMedCrossRefGoogle Scholar
  104. 104.
    Zein JG, Menegay MC, Singer ME, et al. Cost effectiveness of bronchial thermoplasty in patients with severe uncontrolled asthma. J Asthma. 2016;53:194–200. [PubMed:26377375]PubMedCrossRefGoogle Scholar
  105. 105.
    Doeing DC, Husain AN, Naureckas ET, et al. Bronchial thermoplasty failure in severe persistent asthma: a case report. J Asthma. 2013;50:799–801. [PubMed:23651158]PubMedCrossRefGoogle Scholar
  106. 106.
    Moore WC, Castro M. The many “buckets” of severe asthma: moving toward personalized management. J Allergy Clin Immunol Pract. 2017;5:936–7. [PubMed:28689844]PubMedCrossRefGoogle Scholar
  107. 107.
    Fitzpatrick AM, Moore WC. Severe asthma phenotypes — how should they guide evaluation and treatment? J Allergy Clin Immunol Pract. 2017;5:901–8. [PubMed:28689840]PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Ciprandi G, Tosca MA, Silvestri M, Ricciardolo FLM. Inflammatory biomarkers for asthma endotyping. Expert Rev Clin Immunol. 2017;13:715–21. [PubMed:28347164]PubMedCrossRefGoogle Scholar
  109. 109.
    Glass TA, Goodman SN, Hernan MA, Samet JM. Causal inference in public health. Annu Rev Public Health. 2013;34:61–75. [PubMed:23297653]PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Passalacqua G. Anti-interleukin 5 therapies in severe asthma. Lancet Respir Med. 2017;5:537–8. [PubMed:28576696]PubMedCrossRefGoogle Scholar
  111. 111.
    Bunyavanich S, Schadt EE. Systems biology of asthma and allergic diseases: a multiscale approach. J Allergy Clin Immunol. 2015;135:31–42. [PubMed:25468194]PubMedCrossRefGoogle Scholar
  112. 112.
    Park HW, Tantisira KG, Weiss ST. Pharmacogenomics in asthma therapy: where are we and where do we go? Annu Rev Pharmacol Toxicol. 2014;55:129–47. [PubMed:25292431]PubMedCrossRefGoogle Scholar
  113. 113.
    Heaney LG, Mcgarvey LPA. Personalised medicine for asthma and chronic obstructive pulmonary disease. Respiration. 2017;93:153–61. [PubMed:28110335]PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Fang Chen
    • 1
  • Jia-Ying Zhang
    • 2
  • Hong-Kuan Yang
    • 2
  • Fang Wang
    • 2
  1. 1.The First Affiliated Hospital of Zhejiang Chinese Medical UniversityHangzhouChina
  2. 2.First Clinical Medical College of Zhejiang Chinese Medical UniversityHangzhouChina

Personalised recommendations